WHO Raises Alert Over Critical Scarcity of Weight-Loss Jabs

Under 10% of patients who could benefit from GLP-1 drugs such as Wegovy can access them, states the WHO as it issues its first recommendations on the medications.

With in excess of 1,000,000,000 individuals worldwide now living with obesity, it is calling for broader and more equitable availability to GLP-1 medication.

Based on projections, over two billion are projected to be living with obesity by 2030 without intervention.

"The latest guidelines affirms that excess weight is a chronic disease that can be treated with holistic and ongoing care," stated its chief Tedros Adhanom Ghebreyesus.

Significant expense, constrained manufacturing, and logistical bottlenecks are major barriers to universal availability to the jabs that can help people shift considerable body mass, says the organization.

Weight-Loss Drug Scarcity

Despite the present best projected scenario, the manufacturing of these medications might only reach approximately 100 million people – less than 10% of the global need, according to the WHO.

The advice calls on nations and manufacturers to widen availability, via measures such as licensing agreements.

The intellectual property rights on semaglutide – the core component of the drug Wegovy – is scheduled to end in several countries in 2026.

The Way Obesity Injections Operate

GLP-1 drugs mimick a natural hormone to slow digestion, suppress the appetite and increase satiety so users consume fewer calories.

Individuals commonly see weight reduction in the initial weeks of beginning the weekly injections.

Research indicates patients may put most of the weight back on after a year of discontinuing the drug, because their usual hunger return.

To be overweight or obese increases your chance for contracting medical conditions, including type 2 diabetes, heart disease, stroke, and some cancers.

Obesity impacts people in every country and was associated with millions of deaths worldwide in 2024, as per the health agency.